Restructuring |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Restructuring and Related Activities [Abstract] | |
| Restructuring | 13. Restructuring On August 21, 2024, the Company announced a restructuring plan to reduce the Company’s workforce by approximately 32% in response to the Company's announcement on August 20, 2024 that it planned to halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. The Company recorded a total restructuring charge of $2.6 million, which consisted of one-time termination benefits such as severance costs and related benefits. As of March 31, 2026, no one-time termination benefits remain payable. As of December 31, 2025, $0.2 million of one-time termination benefits remained payable and were recorded within the accrued liabilities and other liabilities line items on the Company's condensed balance sheet. The Company paid $0.2 million of the liability during the three months ended March 31, 2026 and $0.4 million during the three months ended March 31, 2025. There were no restructuring charges for the three months ended March 31, 2026 and 2025. Restructuring payments commenced in September 2024 and were completed in March 2026. |